SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 422.34 |
| Enterprise Value ($M) | 372.08 |
| Book Value ($M) | -8.80 |
| Book Value / Share | -0.21 |
| Price / Book | -47.98 |
| NCAV ($M) | -18.38 |
| NCAV / Share | -0.43 |
| Price / NCAV | -22.98 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -1.09 |
| Return on Assets (ROA) | -0.71 |
| Return on Equity (ROE) | n/a |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 5.81 |
| Current Ratio | 6.01 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 276.13 |
| Assets | 285.71 |
| Liabilities | 294.51 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 90.40 |
| Operating Income | -96.78 |
| Net Income | -126.87 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -96.77 |
| Cash from Investing | -20.61 |
| Cash from Financing | 194.62 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Adage Capital Management, L.P. | 6.94 | -21.62 | |
| 13G/A | Morgan Stanley | 1.80 | -65.34 | |
| 13D/A | Pontifax Management III G.P. (2011) Ltd. | 4.40 | -30.85 | |
| 13G/A | Ra Capital Management, L.p. | 7.10 | 3.98 | |
| 13G/A | Menora Mivtachim Holdings Ltd. | 5.47 | 0.00 | |
| 13G/A | Rtw Investments, Lp | 9.99 | 185.51 | |
| 13G/A | Point72 Asset Management, L.P. | 3.60 | -40.85 | |
| 13G/A | Great Point Partners Llc | 1.80 | -71.04 | |
| 13G/A | Cowen And Company, Llc | 4.30 | -21.77 | |
| 13G | BlackRock, Inc. | 5.90 | 0.00 | |
| 13D/A | Arkin Moshe | 4.44 | ||
| 13G/A | Stonepine Capital Management, LLC | 0.00 | -100.00 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A (Amendment No. 1) | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 81,485 | 642,272 | 12.69 | |
| 64,940 | 391,153 | 16.60 | |
| 75,453 | 344,933 | 21.87 | |
| 61,665 | 250,453 | 24.62 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| TRVI – Trevi Therapeutics, Inc. | TSBX – Turnstone Biologics Corp. |
| TVTX – Travere Therapeutics, Inc. | VCEL – Vericel Corporation |
| VERA – Vera Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io